172 related articles for article (PubMed ID: 35982591)
21. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathologic features of secretory breast carcinoma].
Zhang F; Shi M; Liao Q; Zhou CM
Zhonghua Zhong Liu Za Zhi; 2019 Aug; 41(8):628-632. PubMed ID: 31434456
[No Abstract] [Full Text] [Related]
23. Secretory carcinoma of the breast with multiple distant metastases in the brain and unfavorable prognosis: a case report and literature review.
Tang H; Zhong L; Jiang H; Zhang Y; Liang G; Chen G; Xie G
Diagn Pathol; 2021 Jun; 16(1):56. PubMed ID: 34162406
[TBL] [Abstract][Full Text] [Related]
24. Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.
Prescrire Int; 2013 Dec; 22(144):298-303. PubMed ID: 24600734
[TBL] [Abstract][Full Text] [Related]
25. A case of ductal carcinoma with squamous differentiation in malignant phyllodes tumor.
Sugie T; Takeuchi E; Kunishima F; Yotsumoto F; Kono Y
Breast Cancer; 2007; 14(3):327-32. PubMed ID: 17690514
[TBL] [Abstract][Full Text] [Related]
26. HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX.
Tozbikian GH; Zynger DL
Breast J; 2018 Jul; 24(4):535-540. PubMed ID: 29498449
[TBL] [Abstract][Full Text] [Related]
27. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
[TBL] [Abstract][Full Text] [Related]
28. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
29. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
[TBL] [Abstract][Full Text] [Related]
30. [Synchronous and Unilateral Breast Cancers(Invasive Lobular Carcinoma and Non-Invasive Ductal Carcinoma) - A Case Report].
Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T
Gan To Kagaku Ryoho; 2018 Jan; 45(1):73-75. PubMed ID: 29362312
[TBL] [Abstract][Full Text] [Related]
31. Current management of ductal carcinoma in situ.
Barth A; Brenner RJ; Giuliano AE
West J Med; 1995 Oct; 163(4):360-6. PubMed ID: 7483593
[TBL] [Abstract][Full Text] [Related]
32. Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ.
Arvold ND; Punglia RS; Hughes ME; Jiang W; Edge SB; Javid SH; Laronga C; Niland JC; Theriault RL; Weeks JC; Wong YN; Lee SJ; Hassett MJ
Cancer; 2012 Dec; 118(24):6022-30. PubMed ID: 22674478
[TBL] [Abstract][Full Text] [Related]
33. Overview of the biology and management of ductal carcinoma in situ of the breast.
Frykberg ER; Bland KI
Cancer; 1994 Jul; 74(1 Suppl):350-61. PubMed ID: 8004607
[TBL] [Abstract][Full Text] [Related]
34. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
Kuerer HM; Rauch GM; Krishnamurthy S; Adrada BE; Caudle AS; DeSnyder SM; Black DM; Santiago L; Hobbs BP; Lucci A; Gilcrease M; Hwang RF; Candelaria RP; Chavez-MacGregor M; Smith BD; Arribas E; Moseley T; Teshome M; Miggins MV; Valero V; Hunt KK; Yang WT
Ann Surg; 2018 May; 267(5):946-951. PubMed ID: 28549010
[TBL] [Abstract][Full Text] [Related]
35. Mastectomy without malignancy after carcinoma diagnosed by large-core stereotactic breast biopsy.
Casey M; Rosenblatt R; Zimmerman J; Fineberg S
Mod Pathol; 1997 Dec; 10(12):1209-13. PubMed ID: 9436965
[TBL] [Abstract][Full Text] [Related]
36. An analysis of predictive biomarkers in routine histopathological reporting of infiltrating ductal breast carcinoma in a tertiary hospital in Malaysia with a focus on limitations and directions for future development.
Teoh KH; Looi LM; Sabaratnam S; Cheah PL; Nazarina AR; Mun KS
Malays J Pathol; 2011 Jun; 33(1):35-42. PubMed ID: 21874750
[TBL] [Abstract][Full Text] [Related]
37. Local recurrence of mammary Paget's disease after nipple-sparing mastectomy and implant breast reconstruction: a case report and literature review.
Pu Q; Zhao Q; Gao D
World J Surg Oncol; 2022 Sep; 20(1):285. PubMed ID: 36064544
[TBL] [Abstract][Full Text] [Related]
38. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
39. CDX2-positive breast cancer presented with axillary lymph node metastases: A case report.
Hoshina H; Takei H; Sakatani T; Naito Z
Cancer Treat Res Commun; 2021; 26():100300. PubMed ID: 33421821
[TBL] [Abstract][Full Text] [Related]
40. Secretory carcinoma of the breast: A case report.
Pohlodek K; Mečiarová I; Grossmann P; Martínek P; Kinkor Z
Int J Surg Case Rep; 2019; 56():74-77. PubMed ID: 30852371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
